China Pancreatic Cancer Diagnostic Market Size & Outlook
China pancreatic cancer diagnostic market, 2018-2030 (US$M)
Related Markets
China pancreatic cancer diagnostic market highlights
- The China pancreatic cancer diagnostic market generated a revenue of USD 157.5 million in 2023 and is expected to reach USD 248.2 million by 2030.
- The China market is expected to grow at a CAGR of 6.7% from 2024 to 2030.
- In terms of segment, outpatient facilities was the largest revenue generating end use in 2023.
- Home Care is the most lucrative end use segment registering the fastest growth during the forecast period.
Pancreatic cancer diagnostic market data book summary
| Market revenue in 2023 | USD 157.5 million |
| Market revenue in 2030 | USD 248.2 million |
| Growth rate | 6.7% (CAGR from 2023 to 2030) |
| Largest segment | Outpatient facilities |
| Fastest growing segment | Home Care |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
| Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
Other key industry trends
- In terms of revenue, China accounted for 4.6% of the global pancreatic cancer diagnostic market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan pancreatic cancer diagnostic market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 203.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pancreatic Cancer Diagnostic Market Scope
Pancreatic Cancer Diagnostic Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China pancreatic cancer diagnostic market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 62.48% in 2023. Horizon Databook has segmented the China pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The incidence of pancreatic cancer in China has been steadily increasing due to lifestyle changes, dietary habits, and an aging population. Companies are engaged in developing new therapies to treat pancreatic cancer. Companies have entered into collaborations and partnership agreements to provide MCED tests in the country.
Moreover, several biotechnology companies have initiated trials in China, as clinical trial regulations are lenient. Companies expect higher approvals for MCED tests in China than in European or Latin American countries, where trials required for approval & reimbursement are expensive.
Reasons to subscribe to China pancreatic cancer diagnostic market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China pancreatic cancer diagnostic market databook
-
Our clientele includes a mix of pancreatic cancer diagnostic market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into China pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China pancreatic cancer diagnostic market size, by end use, 2018-2030 (US$M)
China Pancreatic Cancer Diagnostic Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
